Alzheimer-kór: vizsgálatok itt: Lengyelország
17 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- No phaseTaking peopleInRAD Observational Study
- Where
- Warsaw
- Életkor
- 18 év and over
- People
- 50 000 worldwide
- Run by
- Stichting International Registry for Alzheimer's Disease and other Dementias Foundation
See details and how to joinNCT07213700 - 2/3. fázisTaking peopleSafety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
- Where
- Cracow, Katowice, Lublin, Poznan, Sochaczew, Staszow, Warsaw, Wroclaw, Wrocław, Zabrze
- Életkor
- 55 év to 90 év
- People
- 300 worldwide
- Run by
- Exciva GmbH
See details and how to joinNCT07284472 · EU 2024-517388-22-00 - 2. fázisTaking peopleStudy to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease
- Where
- Bydgoszcz, Cracow, Scinawa, Szczecin, Warsaw, Wroclaw
- Életkor
- 50 év to 90 év
- People
- 450 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07781657 · EU 2026-526158-14-00 - 2. fázisTaking peopleA Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
- Where
- Bydgoszcz, Katowice, Ścinawa
- Életkor
- 55 év and over
- People
- 370 worldwide
- Run by
- Intra-Cellular Therapies, Inc.
See details and how to joinNCT06540833 - 3. fázisTaking peopleA Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
- Where
- Bydgoszcz, Chorzow, Cracow, Katowice, Poznan, Sochaczew, Wrocław
- Életkor
- 55 év to 90 év
- People
- 426 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07011745 · EU 2025-520612-34-00 - 3. fázisTaking peopleA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
- Where
- Gdansk, Ilawa, Lodz, Lublin, Poznan, Sochaczew
- Életkor
- 55 év to 90 év
- People
- 406 worldwide
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06585787 · EU 2024-516363-92-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
- Where
- Bialystok, Gdansk, Poznan, Torun
- Életkor
- 60 év to 85 év
- People
- 586 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06976216 · EU 2025-520746-30-00 - 3. fázisTaking peopleScreening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
- Where
- B?dzin, Bia?ystok, Bydgoszcz, Gdansk, Gda?sk, Katowice, Krakow, Lublin, ?ód?, ?ory, Późna, Rzeszów, Ścinawa, Sopot, Warsaw, Wroc?aw, Zabrze
- Életkor
- 50 év to 90 év
- People
- 80 000 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07177352 - 3. fázisTaking peopleOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
- Where
- Gdansk, Ilawa, Katowice, Lodz, Łódź, Lublin, Poznan, Scinawa, Sochaczew
- Életkor
- 55 év to 90 év
- People
- 1000 worldwide
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT05980949 · EU 2023-504151-27-00 - 3. fázisTaking peopleA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
- Where
- Łódź, Scinawa
- Életkor
- 55 év to 90 év
- People
- 500 worldwide
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06126224 · EU 2023-504416-16-00 - 3. fázisTaking peopleA Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
- Where
- Bydgoszcz, Chorzow, Cracow, Katowice, Poznan, Sochaczew, Wrocław
- Életkor
- 55 év to 90 év
- People
- 650 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06937229 · EU 2024-519994-20-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
- Where
- Katowice, Oswiecim, Wroclaw
- Életkor
- 60 év to 85 év
- People
- 586 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06976203 · EU 2025-520747-32-00 - No phaseTaking peopleCervical Lymphatic Microsurgery in Alzheimer's Disease
- Where
- Gdansk, Słupsk
- Életkor
- 18 év and over
- People
- 30
- Run by
- Daniel Maliszewski
See details and how to joinNCT07857759 - 2. fázisTaking peopleA Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
- Where
- Gdansk, Krakow, Lublin, Plewiska, Poznan, Warszawa
- Életkor
- 55 év to 90 év
- People
- 300 worldwide
- Run by
- MapLight Therapeutics
See details and how to joinNCT06887192 · EU 2024-519820-26-00 - 2. fázisTaking peopleA study to assess the efficacy and safety of ITI-1284 in the treatment of Psychosis Associated with Alzheimer's Disease
- Where
- Bydgoszcz, Katowice, Ścinawa
- Életkor
- 18 év and over
- People
- 216 worldwide
- Run by
- Intra-Cellular Therapies Inc.
See details and how to join2024-513035-25-00 · EU 2024-513035-25-00 - 2. fázisCsak meghívásosAn Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
- Where
- Gdansk, Krakow, Plewiska, Poznan, Warsaw
- Életkor
- 55 év to 91 év
- People
- 210 worldwide
- Run by
- MapLight Therapeutics
See details and how to joinNCT07459660 · EU 2025-521757-16-00 - 2. fázisTaking peopleEfficacy and Safety of Dimethyl Fumarate Among Patients with Mild Cognitive Impairment and Dementia Due to Alzheimer's Disease
- Where
- Lodz
- Életkor
- 55 év to 90 év
- People
- 30
- Run by
- Medical University of Lodz
See details and how to joinNCT06850597